TY - JOUR
T1 - Care of patients with non-small-cell lung cancer stage III - The Central European real-world experience
AU - Zemanova, Milada
AU - Pirker, Robert
AU - Petruzelka, Lubos
AU - Zbozínkova, Zuzana
AU - Jovanovic, Dragana
AU - Rajer, Mirjana
AU - Bogos, Krisztina
AU - Purkalne, Gunta
AU - Ceriman, Vesna
AU - Chaudhary, Subhash
AU - Richter, Igor
AU - Kufa, Jirí
AU - Jakubikova, Lenka
AU - Zemaitis, Marius
AU - Cernovska, Marketa
AU - Koubkova, Leona
AU - Vilasova, Zdenka
AU - Dieckmann, Karin
AU - Farkas, Attila
AU - Spasic, Jelena
AU - Fröhlich, Katerina
AU - Tiefenbacher, Andreas
AU - Hollosi, Virag
AU - Kultan, Juraj
AU - Kolarová, Iveta
AU - Votruba, Jiri
N1 - Funding Information:
This work was supported by the Czech Lung Cancer Cooperative Group (Kooperativní skupina pro léčbu plicní rakoviny, spolek).
Publisher Copyright:
© 2020 2020 Milada Zemanova, Robert Pirker, Lubos Petruzelka, Zuzana Zbozínkova, Dragana Jovanovic, Mirjana Rajer, Krisztina Bogos, Gunta Purkalne, Vesna Ceriman, Subhash Chaudhary, Igor Richter, Jirí Kufa, Lenka Jakubikova, Marius Zemaitis, Marketa Cernovska, Leona Koubkova, Zdenka Vilasova, Karin Dieckmann, Attila Farkas, Jelena Spasic, Katerina Fröhlich, Andreas Tiefenbacher, Virag Hollosi, Juraj Kultan, Iveta Kolarová, Jiri Votruba, published by Sciendo.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5/28
Y1 - 2020/5/28
N2 - Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.
AB - Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.
KW - diagnostic procedures
KW - multimodality treatment
KW - non-small-cell lung cancer
KW - stage III
UR - https://www.scopus.com/pages/publications/85085630493
U2 - 10.2478/raon-2020-0026
DO - 10.2478/raon-2020-0026
M3 - Article
C2 - 32463394
AN - SCOPUS:85085630493
SN - 1318-2099
VL - 54
SP - 209
EP - 220
JO - Radiology and Oncology
JF - Radiology and Oncology
IS - 2
ER -
SDG 3 Good Health and Well-being